A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial. Enoxaparin Versus Unfractionated Heparin in Non-ST-Segment Elevation Acute Coronary Syndromes

Journal of the American College of Cardiology

Volumn 48, Issue 7, 2006, Pages 1346-1354

  Cohen, Marc ^a   Mahaffey, Kenneth W ^b   Pieper, Karen ^b   Pollack Jr , Charles V ^d   Antman, Elliott M ^e   Hoekstra, James ^c   Goodman, Shaun G ^f   Langer, Anatoly ^f   Col, Jacques J ^g   White, Harvey D ^h   Califf, Robert M ^b   Ferguson, James J ⁱ  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^d PENNSYLVANIA HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h GREEN LANE HOSPITAL   (New Zealand)

ⁱ ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; THROMBIN INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; CORONARY ARTERIOSCLEROSIS; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; TREATMENT OUTCOME;

EID: 33748950070     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.05.058     Document Type: Article

References (14)

1. The SYNERGY Trial Investigators. High-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
2. Braunwald E., Antman E.M., Beasely J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article. Circulation 106 (2002) 1893-1900
3. Bertrand M.E., Simoons M.L., Fox K.A., et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST-segment elevation: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 21 (2000) 1406-1432
4. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337 (1997) 447-452
5. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 100 (1999) 1593-1601
6. Antman E.M., Cohen M., Radley D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 100 (1999) 1602-1608
7. Goodman S.G., Cohen M., Bigonzi F., et al. Randomized trial of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: 1-year results of the ESSENCE study. J Am Coll Cardiol 36 (2000) 693-698
8. Goodman S.G., Fitchett D., Armstrong P.W., Tan M., Langer A., and Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 21 107 (2003) 238-244
9. SYNERGY Executive Committee. The SYNERGY trial: study design and rationale. Am Heart J 143 (2002) 952-960
10. Boersma E., Pieper K.S., Steyerberg E.W., et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Circulation 101 (2000) 2557-2567
11. Cohen M., Theroux P., Borzak S., et al., ACUTE II Investigators. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. Am Heart J 144 (2002) 470-477
12. Blazing M.A., de Lemos J.A., White H.D., et al., A-to-Z Investigators. Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 292 (2004) 55-64
13. Petersen J.L., Mahaffey K.W., Hasselblad V., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes. A systematic overview. JAMA 292 (2004) 89-96
14. Diener H.C., Bogousslavsky J., Brass L.M., et al., MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337